NO20083761L - Tumorterapi med et antistoff for vaskulaer endotel vekst faktor og et antistoff for human epitel vekst faktor reseptor type 2 - Google Patents
Tumorterapi med et antistoff for vaskulaer endotel vekst faktor og et antistoff for human epitel vekst faktor reseptor type 2Info
- Publication number
- NO20083761L NO20083761L NO20083761A NO20083761A NO20083761L NO 20083761 L NO20083761 L NO 20083761L NO 20083761 A NO20083761 A NO 20083761A NO 20083761 A NO20083761 A NO 20083761A NO 20083761 L NO20083761 L NO 20083761L
- Authority
- NO
- Norway
- Prior art keywords
- antibody
- growth factor
- vascular endothelial
- receptor type
- tumor therapy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06111523 | 2006-03-22 | ||
EP06021815 | 2006-10-18 | ||
PCT/EP2007/002448 WO2007107329A1 (en) | 2006-03-22 | 2007-03-20 | Tumor therapy with an antibody for vascular endothelial groeth factor and an antibody for human epithelial growth factor receptor type 2 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20083761L true NO20083761L (no) | 2008-10-09 |
Family
ID=37998279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20083761A NO20083761L (no) | 2006-03-22 | 2008-09-01 | Tumorterapi med et antistoff for vaskulaer endotel vekst faktor og et antistoff for human epitel vekst faktor reseptor type 2 |
Country Status (25)
Country | Link |
---|---|
US (4) | US20070224203A1 (ja) |
EP (2) | EP2364732B1 (ja) |
JP (2) | JP5795463B2 (ja) |
KR (1) | KR101089070B1 (ja) |
AR (1) | AR059982A1 (ja) |
BR (1) | BRPI0709025A2 (ja) |
CA (1) | CA2645891A1 (ja) |
CR (1) | CR10244A (ja) |
DK (2) | DK1998805T3 (ja) |
EC (1) | ECSP088753A (ja) |
ES (2) | ES2595238T3 (ja) |
HK (1) | HK1131037A1 (ja) |
HU (1) | HUE029615T2 (ja) |
IL (1) | IL193675A0 (ja) |
MA (1) | MA30290B1 (ja) |
MX (1) | MX2008012014A (ja) |
MY (1) | MY151449A (ja) |
NO (1) | NO20083761L (ja) |
NZ (1) | NZ570921A (ja) |
PL (2) | PL1998805T3 (ja) |
RU (1) | RU2538664C2 (ja) |
SG (1) | SG170730A1 (ja) |
SI (2) | SI1998805T1 (ja) |
TW (1) | TW200812615A (ja) |
WO (1) | WO2007107329A1 (ja) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
KR101135233B1 (ko) * | 2000-05-19 | 2012-04-12 | 제넨테크, 인크. | ErbB 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
ZA200509059B (en) | 2003-05-30 | 2007-01-31 | Genentech Inc | Treatment with anti-VEGF antibodies |
UA90480C2 (uk) * | 2004-07-22 | 2010-05-11 | Джэнэнтэк, Инк. | Фармацевтична композиція, що має протипухлинну активність, яка включає антитіло до her2 |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Her阻害剤を用いた治療のための患者の選択 |
CN101141981A (zh) | 2005-01-21 | 2008-03-12 | 健泰科生物技术公司 | Her抗体的固定剂量给药 |
ES2440481T3 (es) | 2005-02-23 | 2014-01-29 | Genentech, Inc. | Prolongación del tiempo hasta la progresión de la enfermedad o supervivencia en pacientes de cáncer de ovario usando pertuzumab |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
US20080050385A1 (en) * | 2006-08-21 | 2008-02-28 | Thomas Friess | Tumor therapy with an anti-vegf antibody |
CL2008000614A1 (es) | 2007-03-02 | 2008-09-05 | Genentech Inc F Hoffmann La Ro | Metodo para tratar un paciente con un tipo de cancer que expresa el receptor her3 a un nivel bajo mediante la administracion de un inhibidor de la dimerizacion de her. |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
US8268314B2 (en) | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
KR101397088B1 (ko) | 2011-06-10 | 2014-05-19 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
WO2012169822A2 (ko) * | 2011-06-10 | 2012-12-13 | 강원대학교산학협력단 | 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 |
IL301603A (en) | 2011-10-14 | 2023-05-01 | Genentech Inc | Pertuzumab, trastuzumab, docetaxel and carboplatin for use in the preoperative treatment of a patient |
IN2014DN11157A (ja) | 2012-07-13 | 2015-10-02 | Roche Glycart Ag | |
SG10201913932VA (en) | 2013-03-13 | 2020-03-30 | Genentech Inc | Antibody formulations |
SG10201911353WA (en) | 2013-04-16 | 2020-02-27 | Genentech Inc | Pertuzumab variants and evaluation thereof |
MX2016014007A (es) | 2014-04-25 | 2017-01-11 | Genentech Inc | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. |
BR112017004393A2 (pt) | 2014-09-15 | 2018-02-27 | Genentech Inc | formulações de anticorpo |
JP6822980B2 (ja) | 2015-05-30 | 2021-01-27 | ジェネンテック, インコーポレイテッド | Her2陽性転移性乳癌の治療方法 |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
JP6914336B2 (ja) | 2016-12-28 | 2021-08-04 | ジェネンテック, インコーポレイテッド | 進行したher2発現がんの治療 |
PT3570884T (pt) | 2017-01-17 | 2020-11-24 | Hoffmann La Roche | Formulações subcutâneas de anticorpo do her2 |
CN116531511A (zh) | 2017-03-02 | 2023-08-04 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
JP2020517273A (ja) | 2017-04-24 | 2020-06-18 | ジェネンテック, インコーポレイテッド | 膜貫通ドメインまたは膜近傍ドメインにおけるErbB2/Her2突然変異 |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
DK1167384T3 (da) | 1992-10-28 | 2007-04-10 | Genentech Inc | Vaskular endotheliel cellevækstfaktor antagonister |
BR9709974A (pt) | 1996-06-27 | 1999-08-10 | Pfizer | Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila |
EP1106183A3 (en) | 1996-10-18 | 2001-09-12 | Genentech, Inc. | Antibodies to erbB2 and their therapeutic uses |
US20020032315A1 (en) * | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
PT1787999E (pt) | 1997-04-07 | 2010-11-11 | Genentech Inc | Anticorpos anti-vegf |
KR100816621B1 (ko) * | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-vegf 항체 |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−4−オン誘導体 |
KR20010071271A (ko) | 1998-05-15 | 2001-07-28 | 존 비. 랜디스 | 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법 |
AU4925499A (en) | 1998-08-27 | 2000-03-21 | Pfizer Products Inc. | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
BR9913315A (pt) | 1998-08-27 | 2001-05-22 | Pfizer Prod Inc | Derivados de quinolin-2-ona úteis como agentes anticâncer |
ATE384792T1 (de) | 1998-11-18 | 2008-02-15 | Genentech Inc | Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern |
EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
AU1687500A (en) | 1998-12-16 | 2000-07-03 | Kyowa Hakko Kogyo Co. Ltd. | Antihuman vegf monoclonal antibody |
EP2016953A3 (en) * | 1998-12-22 | 2009-04-15 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists and uses thereof |
CN1340051A (zh) | 1999-02-11 | 2002-03-13 | 辉瑞产品公司 | 可用作抗癌剂的杂芳基取代的喹啉-2-酮衍生物 |
ATE296839T1 (de) | 1999-03-01 | 2005-06-15 | Genentech Inc | Antikörper zur krebsbehandlung und -diagnose |
US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
ES2223705T3 (es) * | 1999-04-28 | 2005-03-01 | Board Of Regents, The University Of Texas System | Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf. |
EP1187632B1 (en) | 1999-05-14 | 2008-12-03 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
CN101121021B (zh) | 1999-06-25 | 2011-12-07 | 杰南技术公司 | 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 |
ES2282120T3 (es) | 1999-06-25 | 2007-10-16 | Genentech, Inc. | Tratamiento del cancer de prostata con anticuerpos anti-erbb2. |
US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
ES2234698T3 (es) * | 1999-10-19 | 2005-07-01 | MERCK & CO., INC. | Inhibidores de tirosina quinasa. |
UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
PT1106612E (pt) | 1999-11-30 | 2004-06-30 | Pfizer Prod Inc | Derivados de quinolina uteis para inibir a farnesil-proteina-transferase |
HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
US20060036086A1 (en) | 2002-03-12 | 2006-02-16 | Jain Rakesh K | Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases |
EP2289942B1 (en) | 2002-04-10 | 2013-07-31 | Genentech, Inc. | Anti-HER2 antibody variants |
ZA200509059B (en) | 2003-05-30 | 2007-01-31 | Genentech Inc | Treatment with anti-VEGF antibodies |
US20040243207A1 (en) | 2003-05-30 | 2004-12-02 | Olson Donald R. | Medical implant systems |
WO2005012531A2 (en) | 2003-08-01 | 2005-02-10 | Genentech, Inc. | Antibody cdr polypeptide sequences with restricted diversity |
AR046639A1 (es) | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
PL1718677T3 (pl) | 2003-12-19 | 2012-09-28 | Genentech Inc | Jednowartościowe fragmenty przeciwciała stosowane jako środki lecznicze |
TW200812615A (en) * | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
-
2007
- 2007-03-19 TW TW096109369A patent/TW200812615A/zh unknown
- 2007-03-20 ES ES11164996.8T patent/ES2595238T3/es active Active
- 2007-03-20 MX MX2008012014A patent/MX2008012014A/es active IP Right Grant
- 2007-03-20 EP EP11164996.8A patent/EP2364732B1/en not_active Revoked
- 2007-03-20 WO PCT/EP2007/002448 patent/WO2007107329A1/en active Application Filing
- 2007-03-20 RU RU2008141433/15A patent/RU2538664C2/ru not_active IP Right Cessation
- 2007-03-20 PL PL07711981T patent/PL1998805T3/pl unknown
- 2007-03-20 JP JP2009500761A patent/JP5795463B2/ja not_active Expired - Fee Related
- 2007-03-20 SI SI200731062T patent/SI1998805T1/sl unknown
- 2007-03-20 US US11/725,777 patent/US20070224203A1/en not_active Abandoned
- 2007-03-20 BR BRPI0709025-0A patent/BRPI0709025A2/pt not_active Application Discontinuation
- 2007-03-20 MY MYPI20083705 patent/MY151449A/en unknown
- 2007-03-20 SI SI200731837A patent/SI2364732T1/sl unknown
- 2007-03-20 AR ARP070101125A patent/AR059982A1/es unknown
- 2007-03-20 KR KR1020087023137A patent/KR101089070B1/ko active IP Right Grant
- 2007-03-20 CA CA002645891A patent/CA2645891A1/en not_active Abandoned
- 2007-03-20 NZ NZ570921A patent/NZ570921A/en not_active IP Right Cessation
- 2007-03-20 PL PL11164996T patent/PL2364732T3/pl unknown
- 2007-03-20 DK DK07711981.6T patent/DK1998805T3/da active
- 2007-03-20 EP EP07711981A patent/EP1998805B1/en not_active Revoked
- 2007-03-20 HU HUE11164996A patent/HUE029615T2/en unknown
- 2007-03-20 SG SG201101893-4A patent/SG170730A1/en unknown
- 2007-03-20 DK DK11164996.8T patent/DK2364732T3/en active
- 2007-03-20 ES ES07711981T patent/ES2392873T3/es active Active
-
2008
- 2008-08-25 IL IL193675A patent/IL193675A0/en not_active IP Right Cessation
- 2008-08-26 CR CR10244A patent/CR10244A/es not_active Application Discontinuation
- 2008-09-01 NO NO20083761A patent/NO20083761L/no not_active Application Discontinuation
- 2008-09-19 EC EC2008008753A patent/ECSP088753A/es unknown
- 2008-09-22 MA MA31255A patent/MA30290B1/fr unknown
-
2009
- 2009-09-30 HK HK09109049.3A patent/HK1131037A1/xx not_active IP Right Cessation
-
2010
- 2010-11-16 US US12/947,264 patent/US9090700B2/en not_active Expired - Fee Related
-
2012
- 2012-07-13 JP JP2012157442A patent/JP2012207036A/ja active Pending
-
2015
- 2015-06-19 US US14/745,026 patent/US20150283238A1/en not_active Abandoned
-
2017
- 2017-05-10 US US15/591,922 patent/US20170239353A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20083761L (no) | Tumorterapi med et antistoff for vaskulaer endotel vekst faktor og et antistoff for human epitel vekst faktor reseptor type 2 | |
PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
CR20190497A (es) | Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso | |
MY145042A (en) | Humanized monoclonal antibodies to hepatocyte growth factor | |
MX349198B (es) | Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos. | |
UA117570C2 (uk) | Спосіб лікування діабету або діабету, спричиненого ожирінням, або ускладнень при діабеті | |
WO2010054265A3 (en) | Monoclonal antibodies to fibroblast growth factor receptor 2 | |
UA94734C2 (ru) | ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ | |
EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
IN2012DN02826A (ja) | ||
AR068532A1 (es) | Inhibicion de angiogenesis | |
MX359516B (es) | Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular. | |
UA106756C2 (uk) | Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа | |
JO3265B1 (ar) | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض | |
EA200701519A1 (ru) | Живая аттенуированная ротавирусная вакцина для перорального введения | |
UA99633C2 (ru) | Антитело, специфически связывающееся с человеческим белком ron | |
WO2008142303A3 (fr) | Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer | |
CA2725873A1 (en) | Monoclonal antibodies to basic fibroblast growth factor | |
HRP20161147T1 (hr) | Farmaceutski sastav i postupak njegove proizvodnje | |
ATE392219T1 (de) | Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs | |
DE60111515D1 (de) | Kombinationstherapie mit keratinozyten-wachstumfaktor und ein epidermis-wachstumfaktor inhibitor | |
SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
CA2755897A1 (en) | Treatment of cancers with immunostimulatory hiv tat derivative polypeptides | |
UA95797C2 (ru) | Терапия опухолей с использованием сосудистого эндотелиального фактора роста и антитела к рецептору типа 2 человеческого эпителиального фактора роста | |
MX2022015769A (es) | Tubulisinas y conjugados de proteina-tubulisina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |